Key Findings
The North American pain management market is evolving at a CAGR of 3.62% during the forecasting years of 2019-2027. The respective growth can be reasoned to the humongous population of the aging generation in the region and the favorable regulatory conditions prevalent in the market. The United States and Canada are considered in the market study.

MARKETING INSIGHTS
There is a higher consumption rate of pain medication with fewer side-effects. This is a major attributing factor for the North America pain management market. Recent development in the technology for the advancement of abuse-deterrent drugs in the region is positively impacting the North American market. The United States market for pain management drug held the largest market share in 2018 due to favorable healthcare reforms in the country to improve the affordability of such medications.

Competitive Insights
GlaxoSmithKline, Purdue Pharma L.P., Acura Pharmaceuticals, Inc., Novartis, Daiichi Sankyo, Inc., Egalet Corp., Eli Lilly and Company, Insys Therapeutics, Inc., Abbott Laboratories, Hikma Pharmaceuticals PLC, Johnson & Johnson, Lupin Ltd., Pfizer, Inc., Merck & Co., Inc. and Cipher Pharmaceuticals Inc. are the eminent market players in the pain management market in the North America region.